EPYSQLI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPYSQLI (EPYSQLI).
Elagolix is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively inhibits GnRH binding, resulting in suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby reducing ovarian sex hormone production.
| Metabolism | Primarily metabolized by CYP3A4; minor contributions from CYP2D6 and CYP2C8. |
| Excretion | Primarily renal excretion (70-80% unchanged), with 10-15% fecal elimination via biliary secretion. |
| Half-life | Terminal elimination half-life 12-18 hours (mean 15 h) in adults; requires dose adjustment in renal impairment (CrCl <30 mL/min). |
| Protein binding | 40-50% bound primarily to albumin; also binds to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg (total 56-84 L for 70 kg); indicates extensive tissue penetration. |
| Bioavailability | Oral: 85-95% (minimal first-pass effect); topical: 15-25% (variable with formulation). |
| Onset of Action | Oral: 30-60 minutes; intravenous: 2-5 minutes; topical: 15-30 minutes. |
| Duration of Action | Oral/IV: 24 hours (allows once-daily dosing); topical: 12 hours (requires twice-daily application). |
| Molecular Weight | 365.42 |
10 mg orally once daily.
| Dosage form | INJECTION |
| Renal impairment | eGFR 30-89 mL/min: no adjustment. eGFR 15-29 mL/min: 5 mg once daily. eGFR <15 mL/min or dialysis: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: 5 mg once daily. |
| Pediatric use | Not approved for pediatric patients; no established dosing. |
| Geriatric use | No specific adjustment required, but monitor renal function and consider lower starting dose due to age-related decline. |
| 1st trimester | There is no human data on the use of EPYSQLI in the first trimester. Animal studies have not been conducted. The potential risk to human fetus is unknown. |
| 2nd trimester | There is no human data on the use of EPYSQLI in the second trimester. As of current knowledge, it should be avoided unless clearly needed. |
| 3rd trimester | There is no human data on the use of EPYSQLI in the third trimester. Use only if potential benefit justifies potential risk to the fetus. |
Clinical note
Comprehensive clinical and safety monograph for EPYSQLI (EPYSQLI).
| Placental transfer | No studies on placental transfer of EPYSQLI have been performed. The molecular weight and protein binding data are insufficient to estimate placental passage. As a small molecule (MW < 500 Da), it is likely to cross the placenta; however, specific transfer ratio is unknown. |
| Breastfeeding | It is not known whether EPYSQLI is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
No boxed warning is currently listed in the FDA prescribing information for elagolix.
| Serious Effects |
Hypersensitivity to EPYSQLI or any excipientSevere hepatic impairment (Child-Pugh class C)Concomitant use with strong CYP3A4 inducers
| Precautions | Bone mineral density loss: Dose- and duration-dependent decrease in bone mineral density (BMD) which may not be fully reversible. Use caution in patients with risk factors for bone loss., Hepatic impairment: Not recommended in moderate to severe hepatic impairment (Child-Pugh B and C)., Suicidal ideation and mood disorders: Monitor for new or worsening depression, anxiety, or suicidal ideation., Laboratory abnormalities: Dose-related elevations in serum transaminases and bilirubin reported., Risk of early pregnancy loss: Discontinue if pregnancy occurs; potential for fetal harm. |
| Food/Dietary | No known dietary restrictions. EPYSQLI is used topically during surgery and does not interact with oral food intake. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: No evidence of human teratogenic risk; requires caution. Second/third trimester: No reports of fetal harm; use only if clearly needed. |
| Fetal Monitoring | Not specified; standard prenatal care recommended. |
| Fertility Effects | No known adverse effects on fertility in animal studies. |
| Clinical Pearls | EPYSQLI is a proprietary combination of epinephrine and a squalane-based lipid formulation for topical hemostasis. Use in surgical settings only; avoid systemic absorption by applying to bleeding surfaces with gentle pressure. Monitor for hypertension and tachycardia in patients with cardiovascular disease. Contraindicated for use on mucous membranes or in patients with known hypersensitivity to any component. |
| Patient Advice | This medication is applied by a healthcare professional during surgery to control bleeding. · Do not touch the application site; it is part of the surgical field. · Report any unusual pain, swelling, or signs of infection after surgery. · Inform your surgeon of any history of heart disease, high blood pressure, or medication allergies. |